Sugi Predict

Sugi Predict / Compounds / SCHEMBL5370952

SCHEMBL5370952

SCHEMBL5370952

CCOC(=O)C(C#N)=C1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ KDM4E B2RXH2 7/20 0.51
▸ MAPT P10636 7/20 0.51
▸ ALDH1A1 P00352 9/20 0.46
▸ HPGD P15428 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ TSHR P16473 2/20 0.43
▸ MAPK1 P28482 4/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ GAA P10253 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8202715 0.94 KMT2A (0.49) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL20825386 0.92 MEN1 (0.47) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL29867013 0.91 KDM4E (0.49) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL625332 0.85 MEN1 (0.57) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL3634417 0.85 MEN1 (0.57) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL362584 0.83 MEN1 (0.56) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL14626678 0.83 MEN1 (0.56) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL13310876 0.83 MEN1 (0.56) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL25057561 0.82 KMT2A (0.54) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL12541465 0.81 SMN1; SMN2 (0.39) KMT2AMEN1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606533-B2 3-phenylpropylamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-04-21 — — US disclosed
US-20250353824-A1 3-PHENYLPROPYLAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-11-20 — — US disclosed
US-12102648-B2 Orally-bioavailable nucleoside analogs VenatoRx Pharmaceuticals, Inc. (US) 2024-10-01 — — US disclosed
CN-118139868-A Orally bioavailable nucleoside analogs 维纳拓尔斯制药公司 2024-06-04 — — CN disclosed
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-07-27 — — US disclosed
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-07-27 — — US disclosed
US-11638715-B2 Orally-bioavailable nucleoside analogs VenatoRx Pharmaceuticals, Inc. (US) 2023-05-02 — — US disclosed
US-20230024722-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. 2023-01-26 — — US disclosed
WO-2022265964-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS VenatoRx Pharmaceuticals, Inc. (US) 2022-12-22 — — WO disclosed
EP-3027593-B1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2020-06-10 — — EP disclosed
WO-2015013835-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-02-05 — — WO disclosed
WO-2015013835-A1 PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-02-05 — — WO disclosed
WO-2014041349-A1 TETRAHYDROPYRAN-4-YLETHYLAMINO- OR TETRAHYDROPYRANYL-4-ETHYLOXY-PYRIMIDINES OR -PYRIDAZINES AS ISOPRENYLCYSTEINCARBOXYMETHYL TRANSFERASE INHIBITORS CANCER THERAPEUTICS CRC PTY LTD (AU) 2014-03-20 — — WO disclosed
WO-2014041349-A1 TETRAHYDROPYRAN-4-YLETHYLAMINO- OR TETRAHYDROPYRANYL-4-ETHYLOXY-PYRIMIDINES OR -PYRIDAZINES AS ISOPRENYLCYSTEINCARBOXYMETHYL TRANSFERASE INHIBITORS CANCER THERAPEUTICS CRC PTY LTD (AU) 2014-03-20 — — WO disclosed
US-7166616-B2 Substituted alkanoic acids AVENTIS PHARMA LIMITED (GB) 2007-01-23 — — US disclosed
US-20040006056-A1 For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma AVENTIS PHARMA LIMITED (GB) 2004-01-08 — — US disclosed
EP-1330432-A2 SUBSTITUTED ALKANOIC ACIDS Aventis Pharma Limited (GB) 2003-07-30 — — EP disclosed
WO-2002036553-A2 SUBSTITUTED ALKANOIC ACIDS AVENTIS PHARMA LIMITED (GB) 2002-05-10 — — WO disclosed
US-5034381-A Antagonist CIBA-GEIGY CORPORATION (US) 1991-07-23 — — US disclosed
EP-0323807-A2 Certain 2-substituted adenosine derivatives CIBA-GEIGY AG (CH) 1989-07-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024722-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS SLC29A2, SLC29A1, PNP KMT2A 3232/4885MEN1 4140/4885KDM4E 3750/4885
US-20250353824-A1 3-PHENYLPROPYLAMINE DERIVATIVE SF1, SF3A1, SFXN1 KMT2A 1381/4885MEN1 2763/4885KDM4E 837/4885
US-20040006056-A1 For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma VCAM1, LTB4R, ITGA1 KMT2A 2556/4885MEN1 3272/4885KDM4E 3403/4885
US-12102648-B2 Orally-bioavailable nucleoside analogs SLC29A2, SLC29A1, PNP KMT2A 3232/4885MEN1 4140/4885KDM4E 3750/4885
US-12606533-B2 3-phenylpropylamine derivative SF3A1, SF1, HTR1D KMT2A 1072/4885MEN1 3086/4885KDM4E 260/4885
US-11638715-B2 Orally-bioavailable nucleoside analogs SLC29A2, SLC29A1, PNP KMT2A 3232/4885MEN1 4140/4885KDM4E 3750/4885
US-20230233593-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS SLC29A2, SLC29A1, PNP KMT2A 3232/4885MEN1 4140/4885KDM4E 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.